NovaBay Pharmaceuticals, Inc. (NBY)
After hours:
| Previous Close | 0.7198 |
| Open | 0.7150 |
| Bid | 0.6507 x 1000 |
| Ask | 0.7250 x 1100 |
| Day's Range | 0.6806 - 0.7100 |
| 52 Week Range | 0.3600 - 11.5500 |
| Volume | |
| Avg. Volume | 2,800,203 |
| Market Cap | 3.327M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -74.6100 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.72 |
Business WireNovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
EMERYVILLE, Calif., November 22, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold of favorab
- Business Wire
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
EMERYVILLE, Calif., November 15, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company’s proxy proposals, specifically to authorize and approve the sale of its eyecare business (the "Asset Sale Proposal") and approve the voluntary liquidation and dissolution of the Company (the "Dissolution
